- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04459234
Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC (KETACANCER)
KETACANCER: Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC
The primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation…) and administration protocol (route, posology, duration, administration sequence, premedication).
The secondary objectives are to evaluate in the context of cancer, the analgesic efficacy, the tolerance profile (biological and clinical toxicities) and the quality of life, including anxiety and depression.
In addition, the described parameters will be evaluated as safety and efficacy predictive factors of the Ketamine in oncology.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Almost 382,000 new cancers have been diagnosed in France in 2018. Regular progresses in their management have improved the overall survival of patients, sometimes with sequelae that may be particularly painful. Thus for 20 to 45% of patients treated for breast cancer, pain persists 5 years later.
If remission is a regularly reached target, cancer was also the cause of 157,000 deaths in 2018 in France, preceded by months or years of progression of a chronic disease that regularly causes pain. Pain during cancer (chronic cancer pain for CIM-11) remains a frequent symptom, and its prevalence has slightly changed during the last 20 years.
In the European EPIC study, carried out in 2006, 76% of the cancer patients (and 62% of French patients) presented moderate to severe pains linked to cancer, daily for more than half of them.
Even when identified, chronic cancer pain is still under-treated in 25 to 60% of cases worldwide, including in the most developed countries.
When well-managed, pain's management now allows the relief of almost 80% of patients. Pain's management is based in particular on a precise and adapted use of the different opioids through different routes of administration (oral, transdermal, trans-mucosal, parenteral, etc.).
A neuropathic component of pain exists in almost a third of cases and may require specific treatments when opioids are insufficient. In all cases, the treatment is integrated into a multidisciplinary management, in connection with the ongoing oncological treatments, the loco-regional treatments available (radiotherapy, interventional radiology, etc.) and with an adapted psychosocial management.
Ketamine is an NMDA receptor antagonist (N-Methyl-D-Aspartate) indicated as a high dose anesthetic. It is used in the context of peri-operative pain for its anti-hyperalgesic properties. These properties have led to its use also in palliative care (outside the marketing authorization [AMM]) to treat hyperalgesia linked to the use of high-doses of opioids, as well as depression. For non-cancer pains, ketamine is widely used by centres and consultations specialized in refractory chronic pain management in different pains not relieved by standard treatments: neuropathic pain, fibromyalgia, etc., or even in opioids weaning aid.
The bibliographic data are not homogeneous and of low quality. Despite the weakness of the available data, ketamine is widely used in France in chronic pain in situation of therapeutic impasse. The protocols used vary according to the prescribers and services practices: venous route in general, sometimes subcutaneous or even oral; doses varying from 30 to 200 mg / day, infusion duration varying from a few hours to several days, discontinuous administration by cycle or continuous administration, etc.
Current knowledge is too limited in oncology to have a consensus on the use of ketamine :
- Often retrospective studies with heterogeneous treatment protocols;
- Studied populations also heterogeneous, with insufficiently documented indications;
- Staff not able to answer adequately the questions raised. This situation largely explains the heterogeneity of the Ketamine practices of use in oncology
It is essential to draw up an inventory of the ketamine use by the French CLCCs pain teams and to identify the profile of patients in whom i) the treatment is ineffective and must be avoided regarding toxicities ii) the potential efficacy required further investigations. Built on a methodology close to the OKAPI study, the KETACANCER study will enable to compare indirectly the results of the two studies.
To do this, it is proposed to conduct the KETACANCER prospective study in a precise population defined a priori, and corresponding to the following indications:
- Neuropathic sequelae pain
- Additional effect of morphine
- Morphine weaning.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Julien GAUTIER
- Phone Number: +33 4.26.55.68.29
- Email: julien.gautier@lyon.unicancer.fr
Study Contact Backup
- Name: Gisèle CHVETZOFF, MD
- Phone Number: +33 4.78.78.26.57
- Email: gisele.chvetzoff@lyon.unicancer.fr
Study Locations
-
-
-
Bordeaux, France, 33076
- Institut Bergonié
-
Caen, France
- Centre François Baclesse
-
Clermont-Ferrand, France, 63011
- Centre Jean Perrin
-
Lyon, France, 69008
- Centre Léon Bérard
-
Marseille, France, 13273
- Institut Paoli Calmettes
-
Montpellier, France, 34298
- Institut de Cancérologie de Montpellier
-
Paris, France, 75005
- Institut Curie
-
Reims, France, 51056
- Institut Godinot
-
Rennes, France, 35042
- Centre Eugène Marquis
-
Toulouse, France, 31059
- Institut Universitaire du Cancer (IUCT)
-
Vandoeuvre les nancy, France, 54519
- Institut de Cancérologie de Lorraine Alexis Vautrin
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient at least 18 years old at the day of consenting to the study
- Patient followed for a solid tumour or a hematological malignancy (treated or under treatment)
- Patient presenting cancer chronic pain or post cancer treatment pain
- Patient followed by a CLCC's intractable chronic pain consultation or centre
- Patient with an indication of 1st Ketamine course:
- Analgesic treatment of cancer chronic pain
- Analgesic treatment for a post-cancer treatment chronic pain
- Help for withdrawal from opioid treatment prescribed for a chronic cancer pain
- Patient not previously treated by Ketamine
- Patient covered by a medical insurance
- Patient and/or family did not decline data collection after complete information (information sheet)
Exclusion Criteria:
- Patient presenting chronic pains not related to cancer or its treatments
- Patient with a proven psychotic history
- Patient who is not fluent enough in French
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication
Time Frame: Up to 3 months after inclusion
|
neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation
|
Up to 3 months after inclusion
|
Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of administration protocol
Time Frame: Up to 3 months after inclusion
|
route, posology, duration, administration sequence, premedication
|
Up to 3 months after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate in the context of cancer the antalgic efficacy
Time Frame: Up to 3 months after inclusion
|
Questionnaire: NPSI
|
Up to 3 months after inclusion
|
Evaluate in the context of cancer the antalgic efficacy
Time Frame: Up to 3 months after inclusion
|
Questionnaire: DN4
|
Up to 3 months after inclusion
|
Evaluate in the context of cancer the antalgic efficacy
Time Frame: Up to 3 months after inclusion
|
Questionnaire: PGIC
|
Up to 3 months after inclusion
|
Evaluate in the context of cancer the tolerance profile
Time Frame: Up to 3 months after inclusion
|
The safety will be described mainly on the frequency of adverse events coded using the common toxicity criteria (NCI-CTCAE v5.0) grade.
Descriptive statistics will be provided for characterizing and assessing patient's tolerance to treatment.
Adverse events will be coded according to the MedDRA®.
|
Up to 3 months after inclusion
|
Evaluate in the context of cancer the quality of life including anxiety and depression
Time Frame: Up to 3 months after inclusion
|
Numeric scale (from 0 : no pain to 10: maximum pain)
|
Up to 3 months after inclusion
|
Evaluate in the context of cancer the quality of life including anxiety and depression
Time Frame: Up to 3 months after inclusion
|
Questionnaire: HADS
|
Up to 3 months after inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gisèle CHVETZOFF, MD, Centre Léon Bérard
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Chronic Pain
- Neuralgia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
- ET20-130 - KETACANCER
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Palleon Pharmaceuticals, Inc.RecruitingMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
Clinical Trials on Ketamine use in CLCC sites (indication and administration protocol)
-
Beni-Suef UniversityNot yet recruiting
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science UniversityWithdrawnAnatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditionsUnited States